# NCT03734029 (NCT03734029)

> Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03734029
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Breast Cancer
- Interventions: Trastuzumab deruxtecan (DS-8201a); Capecitabine; Eribulin; Gemcitabine; Paclitaxel; Nab-paclitaxel
- Enrollment: 557
- Primary outcome: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer

## Commentary we found

- YouTube: 155
- Podcasts: 141
- X threads: 45
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03734029

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03734029", "email": "<work email>"}; the inbox owner confirms by the emailed link.